Abstract Submission Deadline: September 16 at 3:00 PM CT. 

Thank you for your interest in participating in the 2026 AOFAS Winter Meeting in Napa, California. AOFAS is currently accepting submissions for Podium Presentations. Please review the requirements below closely before beginning your abstract.

Abstract Submission Fee

NEW THIS YEAR - A non-refundable abstract submission fee of $25 for AOFAS Members and $50 for non-members (per abstract) is due at the time of submission.

The abstract submission fee amount is determined by the AOFAS member type of the Abstract Submitter. AOFAS Members must log in to the submission site using the same email address as their membership profile to ensure the correct fee is charged. If you have trouble logging in, please contact aofasinfo@aofas.org.

Payment of the submission fee is not based on the abstract's acceptance into the AOFAS Winter Meeting Program. Refunds will not be issued for declined abstracts.

Submission Instructions:

As the “Primary Submitter” you are responsible for managing this abstract, which includes adding the presenter and co-authors to the abstract. Co-authors are required to have an aofas.org account before you add them to the abstract. You can check if they already have an account, or they can create a new account here. Co-authors are NOT required to complete a disclosure to submit an abstract. If an abstract is selected, co-authors will then get an email to complete their disclosures, which is required prior to presentation of the abstract. 

Requirements: 

• Paper presenters must register and attend 2026 Winter Meeting in person. Podium presentations cannot be presented virtually.
• Paper presenters must be eligible to participate in Continuing Medical Education, as defined by the ACCME. Click here to read the full policy. Employees and Owners of ineligible companies are not eligible to participate in CME programming. 
• All paper authors are required to complete a disclosure of conflict of interest via Convey Global Disclosure prior to presentation. AOFAS will send instructions to all authors if a paper has been accepted. Individuals without current disclosures on file may be removed from the meeting program.

Additional information:

• Authors are encouraged to use the language to communicate specific regions and motions of the foot and ankle, as published in the Foot & Ankle International editorial
• Your co-authors will receive an e-mail notification from AOFAS that they have been added to the abstract. They must log in to complete their tasks. Their login information is the same as on the AOFAS.org website.
• There is a suggested limit of 500 words for each abstract (excluding the abstract title and authors) - Section word count limits are Introduction/Purpose - 125, Methods - 150, Results - 125, Conclusion – 100
• A single file, figure or table, may be uploaded for each submission (jpg, png, jpeg up to 3MB). Use generic drug and/or device names wherever possible and be sure to keep the submission blinded with no author or institution names.
• The primary submitter will receive an email confirmation when their abstract has been submitted. A second confirmation email will be sent to the primary submitter indicating that the abstract submission has been marked complete.
• The primary submitter may save an abstract and re-visit the submission site as often as necessary to complete. After submitting an abstract, however, the abstract will not be editable. Please review your abstract before submitting to ensure that it is accurate and includes all co-authors.
• Completed abstracts will be reviewed in a anonymized peer-review process by the Program Committee. Notifications will be sent in November. 
• All accepted abstracts will be published in Foot & Ankle Orthopaedics (FAO), an open access scholarly journal of the AOFAS, and the top 50 selected abstracts will be printed in Foot & Ankle International (FAI)® , To opt out, please contact education@aofas.org.